A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

Investigator Site 35, Budapest

Investigator Site 11, Edegem

Investigator Site 7, Ghent

Investigator Site 28, Berlin

Investigator Site 26, Belgrade

Investigator Site 30, Prague

Investigator Site 10, Milan

Investigator Site 37, Charlottesville

Investigator Site 2, Chapel Hill

Investigator Site 41, Jacksonville

Investigator Site 4, Tampa

Investigator Site 1, Cordova

Investigator Site 18, Cleveland

Investigator Site 32, Detroit

Investigator Site 14, Kansas City

Investigator Site 19, Ostrava-Poruba

Investigator Site 3, San Antonio

Investigator Site 5, Napoli

Investigator Site 8, Los Angeles

Investigator Site 42, Carlsbad

Investigator Site 33, Orange

Investigator Site 21, Palo Alto

Investigator Site 12, Portland

Investigator Site 39, Samara

Investigator Site 34, Novosibirsk

Investigator Site 20, Toronto

Investigator Site 25, Montreal

Investigator Site 16, Brno

Investigator Site 49, Aarhus

Investigator Site 50, Bordeaux

Investigator Site 51, Marseille

Investigator Site 52, Szeged

Investigator Site 47, Chiba

Investigator Site 48, Minato

Investigator Site 17, Copenhagen

Investigator Site 45, Tbilisi

Investigator Site 31, Tbilisi

Investigator Site 46, Tbilisi

Investigator Site 38, Roma

Investigator Site 24, Sapporo

Investigator Site 13, Hanamaki-shi

Investigator Site 27, Sendai

Investigator Site 23, Ōsaka-sayama

Investigator Site 22, Suita

Investigator Site 40, Meguro City

Investigator Site 43, Shinjuku-Ku

Investigator Site 44, Hiroshima

Investigator Site 36, Leiden

Investigator Site 9, Gdansk

Investigator Site 29, Katowice

Investigator Site 6, Krakow

Investigator Site 15, Warsaw